Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

ACADIA Pharmaceuticals (ACAD) reported robust Q1 revenues of $244 million, driven by 23% and 11% year-over-year growth in NUPLAZID and DAYBUE sales, respectively, reaffirming its full-year revenue guidance of $1B-$1.1B. A significant near-term catalyst is the upcoming Phase 3 readout for ACP-101 in Prader-Willi syndrome, with the article assigning a 60-65% probability of success for the COMPASS-PWS trial. While a positive outcome could lead to a conservative $400 million in peak annual revenue for ACP-101 and a 10-20% stock upside, the potential downside from failure is estimated at a more limited 10%, leading to a 'Buy' recommendation given ACAD's strong existing product growth.

Analysis

ACADIA Pharmaceuticals' current valuation of $3.9B appears well-supported by its commercial-stage assets, NUPLAZID and DAYBUE. The company reported robust Q1 revenue of $244 million, reflecting year-over-year growth of 23% and 11% for the two drugs, respectively, and reaffirmed its full-year revenue guidance of $1.0B to $1.1B. The primary focus is now on the upcoming Phase 3 COMPASS-PWS trial readout for ACP-101 in Prader-Willi syndrome, a key binary catalyst. The previous Phase 3 trial (CARE-PWS) yielded mixed results, with the 3.2mg dose achieving statistical significance while the 9.6mg dose did not. The analysis posits that this was likely due to a small, non-representative sample and a strong placebo effect, rather than the company's theory of a bell-shaped dose response. The redesigned COMPASS trial, utilizing the successful 3.2mg dose with a larger and more representative patient population, is assigned a 60-65% probability of success. A positive outcome is conservatively estimated to generate $400 million in peak annual revenue, factoring in its second-to-market position behind Soleno Therapeutics and a less convenient three-times-daily dosing regimen. This success scenario is projected to drive a 10-20% increase in stock value, while a failure is estimated to result in a more contained 10% downside, creating an asymmetric risk/reward profile.

Key Decisions for Investors

• Consider the favorable asymmetric risk/reward profile ahead of the COMPASS-PWS trial readout, where the potential 10-20% upside on success is estimated to be greater than the projected 10% downside on failure.
• Recognize that the existing commercial portfolio, with reaffirmed annual revenue guidance of over $1 billion, provides a fundamental valuation floor that helps mitigate the risk of the binary clinical trial outcome.
• Factor in the conservative peak revenue estimate of $400 million for ACP-101, which accounts for its second-to-market status and less competitive dosing schedule compared to Soleno Therapeutics' product.
• Investors should note that while the 60-65% probability of success for ACP-101 is encouraging due to an improved trial design, it still reflects the significant inherent risk of a clinical-stage catalyst that has previously delivered mixed results.